Physician profile
Tinashe Maduke
NPI 1144670894
$12,959.60
in general payments reported to CMS, 2019-2025
13 companies · $4,792 in 2025
The $4,792 reported for 2025 was more than what 92% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $77.87 · 2023: $741 · 2024: $6,931 · 2025: $4,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,370 · Education: $5,500 · Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,369.60 |
| Education | $5,500.00 |
| Food and Beverage | $594.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,653.73 | 2023-2024 | Da Vinci Surgical System |
| Chiesi USA, INC. | $2,934.39 | 2025 | |
| Pulmonx Corporation | $1,766.16 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Veran Medical Technologies, INC. | $131.10 | 2019 | |
| Galvanize Therapeutics, INC | $91.60 | 2025 | Aliya System |
| Medicure Pharma INC. | $88.88 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $77.87 | 2020 | |
| Gilead Sciences, INC. | $54.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $54.15 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $51.49 | 2019 | |
| Pfizer INC. | $25.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.12 | 2024 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tinashe Maduke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.